NEW YORK (GenomeWeb News) – ChromoCure today said that it will collaborate with Genome Research Group in developing technologies for monitoring and determining the efficacy of cancer treatments.
Under the agreement, ChromoCure said that it will have access to GRG's therapeutic modeling protocols and algorithms that use hypothermic modulation and resonance for the non-toxic and non-invasive treatment of cancer. In return, GRG will have access to ChromoCure's chromosomal scanner technology, which includes a series of systems, processes, cell preparation techniques, and diagnostic algorithms.
ChromoCure's systems measure aneuploidy to detect cancer and measure cancer progression. The Reno, Nev.-based firm claims that its scanner is has a 100 percent accuracy rate.